CN110433230A - The therapeutical uses of Chardonnay seed products - Google Patents
The therapeutical uses of Chardonnay seed products Download PDFInfo
- Publication number
- CN110433230A CN110433230A CN201910426268.4A CN201910426268A CN110433230A CN 110433230 A CN110433230 A CN 110433230A CN 201910426268 A CN201910426268 A CN 201910426268A CN 110433230 A CN110433230 A CN 110433230A
- Authority
- CN
- China
- Prior art keywords
- chardonnay
- chardonnay seed
- seed
- diet
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims description 45
- 241000124008 Mammalia Species 0.000 claims description 31
- 230000037356 lipid metabolism Effects 0.000 claims description 7
- 230000007407 health benefit Effects 0.000 abstract description 7
- 235000012054 meals Nutrition 0.000 description 108
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 100
- 239000000047 product Substances 0.000 description 94
- 235000005911 diet Nutrition 0.000 description 66
- 230000037213 diet Effects 0.000 description 66
- 239000000843 powder Substances 0.000 description 53
- 241000699800 Cricetinae Species 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 43
- 235000012000 cholesterol Nutrition 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 239000013589 supplement Substances 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 30
- 235000009754 Vitis X bourquina Nutrition 0.000 description 28
- 235000012333 Vitis X labruscana Nutrition 0.000 description 28
- 240000006365 Vitis vinifera Species 0.000 description 28
- 235000014787 Vitis vinifera Nutrition 0.000 description 28
- 201000010099 disease Diseases 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 28
- 239000000284 extract Substances 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 26
- 208000032928 Dyslipidaemia Diseases 0.000 description 26
- 230000036765 blood level Effects 0.000 description 25
- 235000020940 control diet Nutrition 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- 235000013305 food Nutrition 0.000 description 19
- 235000009200 high fat diet Nutrition 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 208000008589 Obesity Diseases 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 235000020824 obesity Nutrition 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 108010010234 HDL Lipoproteins Proteins 0.000 description 16
- 102000015779 HDL Lipoproteins Human genes 0.000 description 16
- 208000017170 Lipid metabolism disease Diseases 0.000 description 16
- 102000004895 Lipoproteins Human genes 0.000 description 16
- 108090001030 Lipoproteins Proteins 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 15
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 description 15
- 102000007330 LDL Lipoproteins Human genes 0.000 description 15
- 235000012734 epicatechin Nutrition 0.000 description 15
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 230000002440 hepatic effect Effects 0.000 description 13
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- 235000002532 grape seed extract Nutrition 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 11
- 235000010469 Glycine max Nutrition 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 235000012970 cakes Nutrition 0.000 description 10
- 229940087559 grape seed Drugs 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 241000186000 Bifidobacterium Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 229940087603 grape seed extract Drugs 0.000 description 9
- 239000000401 methanolic extract Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000001717 vitis vinifera seed extract Substances 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 9
- 241000606124 Bacteroides fragilis Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 8
- 235000005487 catechin Nutrition 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229950001002 cianidanol Drugs 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 235000015067 sauces Nutrition 0.000 description 8
- 208000034423 Delivery Diseases 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 235000008429 bread Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 235000013372 meat Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 108010076365 Adiponectin Proteins 0.000 description 6
- 102000011690 Adiponectin Human genes 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 6
- 229930182558 Sterol Natural products 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 150000003432 sterols Chemical class 0.000 description 6
- 235000003702 sterols Nutrition 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000009677 vaginal delivery Effects 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 5
- 241000193403 Clostridium Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000833892 Homo sapiens Peroxisomal acyl-coenzyme A oxidase 1 Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 206010033645 Pancreatitis Diseases 0.000 description 5
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 description 5
- 241000192031 Ruminococcus Species 0.000 description 5
- 101150097713 SCD1 gene Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000013351 cheese Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000008268 mayonnaise Substances 0.000 description 5
- 235000010746 mayonnaise Nutrition 0.000 description 5
- 230000037323 metabolic rate Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- 241000305071 Enterobacterales Species 0.000 description 4
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 4
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 description 4
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 description 4
- 102000043296 Lipoprotein lipases Human genes 0.000 description 4
- 208000035180 MODY Diseases 0.000 description 4
- 102000013436 Member 5 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000233805 Phoenix Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 208000004104 gestational diabetes Diseases 0.000 description 4
- 230000004153 glucose metabolism Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588921 Enterobacteriaceae Species 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- 108010090837 Member 5 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 3
- 101000775476 Mus musculus Adiponectin Proteins 0.000 description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 206010036049 Polycystic ovaries Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 238000012754 cardiac puncture Methods 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960002887 deanol Drugs 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 208000006443 lactic acidosis Diseases 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013622 meat product Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000012459 muffins Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000003307 slaughter Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000208140 Acer Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- -1 acetic acid parachlorophenol ester Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000015241 bacon Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000015228 chicken nuggets Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 235000012777 crisp bread Nutrition 0.000 description 2
- 235000021185 dessert Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000018914 glucose metabolism disease Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 235000020166 milkshake Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940014662 pantothenate Drugs 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 101150011814 ABCG51 gene Proteins 0.000 description 1
- 235000010319 Acer grandidentatum Nutrition 0.000 description 1
- 235000010328 Acer nigrum Nutrition 0.000 description 1
- 235000002629 Acer saccharinum Nutrition 0.000 description 1
- 235000010157 Acer saccharum subsp saccharum Nutrition 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241001037822 Bacillus bacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241001047198 Scomberomorus semifasciatus Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241000657513 Senna surattensis Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241001158692 Sonoma Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010067130 Spastic diplegia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000012467 brownies Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 235000019545 cooked cereal Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000021463 dry cake Nutrition 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 235000014089 extruded snacks Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019581 fat taste sensations Nutrition 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000012020 french fries Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 235000019692 hotdogs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013575 mashed potatoes Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 229940090668 parachlorophenol Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000012830 plain croissants Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000012069 sugar maple Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 235000012773 waffles Nutrition 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Dairy Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This disclosure relates to the health benefits of Chardonnay seed products.
Description
The application is that the China of entitled " therapeutical uses of Chardonnay seed products " that the applying date is on April 29th, 2013 is special
The divisional application of sharp application number 201380026061.9.
1. background technique
1.1Metabolic disorder
It is (non-that obesity is well known as many very common diseases such as atherosclerosis, hypertension, 2 patients with type Ⅰ DM
Insulin-dependent diabetes mellitus (NIDDM)), dyslipidemia, coronary heart disease and osteoarthritis and various malignant progressions
Risk factor.It also causes considerable problem by reducing motility and reducing quality of life.Obesity and thus there are also this
The disease incidence of a little diseases is increasing in entire industrialised world.
Term obesity refers to that adipose tissue is excessive.Obesity is preferably regarded as being to confer to health risk in this context
Any degree crosses fattiness.Normally the line of demarcation between obese individuals may be only approximate, but be assigned by obesity
The health risk given may be fat increased continuity.
It will increase premature death and illness such as diabetes, dyslipidemia, hypertension, artery congee Mild Obesity disease
The risk of sample sclerosis, gallbladder disease and certain form of cancer.In the western industrial world, the illness rate of obesity was in the past
Decades in dramatically increase.Due to the high incidence and its health consequences of obesity, prevention and treatment should be one and answer
The public health problem that high-priority considers.
When Energy intaking is more than expenditure, waste heat major storage is in adipose tissue, and if this just putting down only
Weighing apparatus extends, then will lead to obesity, that is, and there are two the component parts of weight balance, and to any one side (intake or expenditure)
It is abnormal all to may cause obesity.This process can be by increasing energy consumption (such as movement) or reducing Energy intaking (example
Such as, diet) it is offset.In addition to movement, diet and food limitation, this be to vast subject it is infeasible, do not have also at present
The compellent treatment of effective and acceptable losing weight.
A kind of possible mode for increasing energy consumption is to increase metabolic rate (metabolic rate).Therefore, pass through increase
Metabolic rate and the drug to work are likely to be suited for treatment obesity, and are also applied for treatment Other diseases such as Atherosclerosis
Change disease, hypertension, diabetes especially diabetes B (NIDDM (Non-Insulin Dependent Diabetes Mellitus)), dyslipidemia, hat
Heart trouble, gallbladder disease, osteoarthritis and different types of cancer such as carcinoma of endometrium, breast cancer, prostate cancer and colon cancer and mistake
Early dead risk.
Thus, identify that the reagent that can increase energy consumption will be desirable.It is preferred that this reagent can be day
Right reagent and avoid side effect relevant to medical compounds.
1.2.Enteron aisle biocoene
The enteron aisle of baby is being sterile before birth.After birth, group is built by environmental bacteria rapidly in enteron aisle and is settled down until building
Stand intensive enteron aisle biocoene.It is thin that the baby of vaginal delivery from its mother's vagina and faecal microbiota obtains intestinal flora cluster
Bacterium.In contrast, by being not exposed to the vagina and faecal microbiota of its mother during the baby due of caesarean birth, and it is thus numerous
The enteron aisle biocoene to spread out is different from the enteron aisle biological flora of vaginal delivery baby in composition.These enteron aisle biocoenes composition
Difference after birth i.e. to be kept for the several months.Similarly, in breast-feeding and those formulations (formula milk, formula)
The difference of enteron aisle biocoene composition is had been observed that between fed infant.
Adult's enteron aisle has about 1013(10,000,000,000,000) different settler (Backhead, F., et are planted
al.(2004)PNAS Volume 101;No 44pp.15718-15723), and traverse many human culture background constructings three
The constant microorganism parting (Arumugam, M.et al. (2011) Nature Vol.473pp.174-180) of kind.Enteron aisle biology
Group is influenced by plant base polyphenol in diet, and it is believed that the microbes be translated into human host can biology
(Rastmanesh, R. (2011), the Chemico-Biol.Interact.Vol.189pp.1-8 utilized;Moco, S.,
F.J.Martin, and S.Rezzi. (2012) J.Proteome Res.Volume 11, pp. 4781-4790).Serve as one kind
Organ, the enteron aisle biocoene are also responsible for the vitamin such as cholecalciferol (vitamin D of conversion and production key25), biology
Plain (biotin), riboflavin (vitamin B2), pantothenate (pantothenate) (vitamin B5), ascorbic acid (vitamin C),
Thiamine (vitamin B1) and folic acid (vitamin B9);Especially it has been found that three kinds of microorganism parting (bacteroids
(Bacteroides), Ruminococcus (Ruminococcus) and melaninogenicus (Prevotella)) in two kinds of (bacteroids
And melaninogenicus).Some polyphenols by Norman doctor Hollenberg, Harvard Medical School medicine professor with its from
The right expression of body is vitamin.However, modern diet, especially western diet may promote comprising a large amount of processed food
It is formed into enteron aisle biocoene, cannot convert or produce these enough or optimised quantity crucial vitamins.
Thus, it identifies " nutrition blank " caused by Traditional Processed Food consumption " can be filled up " and adjusts human intestine's life
Object group and realize health improvement reagent be desirable.It is preferred that this reagent is natural agent and avoids and pharmaceutical compound
The relevant side effect of object.
2. summary of the invention
The disclosure of invention is related to the health benefits of Chardonnay (chardonnay, Xue Dangli, Chardonnay) seed products.
In certain aspects, the disclosure of invention is related to a kind of effectively improving lipid-metabolism in mammal by giving
Amount method of the Chardonnay seed products to improve lipid-metabolism in mammal.
In certain aspects, the disclosure of invention is related to a kind of effectively improving metabolic rate in mammal by giving
Method of the Chardonnay seed products of the amount of (metabolic rate) to improve mammalian metabolism rate.
The disclosure of invention further relates to one kind and effectively treats or prevents fertilizer in mammal by giving to mammal
The Chardonnay seed products of the amount of fat disease are to treat or prevent obesity in mammal, cardiovascular disease, dyslipidemia, exception
The method of lipoproteinemia or metabolism obstacles of blood glucose disease.
The disclosure of invention effectively treats or prevents the lactation by giving to mammal further to one kind
Method of the Chardonnay seed products of the amount of animal center angiosis to treat or prevent mammal angiosis.Certain
In aspect, cardiovascular disease is arteriosclerosis, atherosclerosis, apoplexy, ischemic, endothelial dysfunction disease, peripheral blood vessel
Disease, coronary heart disease, myocardial infarction, cerebral infarction or restenosis.
The disclosure of invention effectively treats or prevents the lactation by giving to mammal further to one kind
Method of the Chardonnay seed products of the amount of dyslipidemia to treat or prevent dyslipidemia in mammal in animal.In
In some aspects, the dyslipidemia is high-density lipoprotein (HDL) cholesterol of hyperlipemia or low blood level.In certain sides
In face, the hyperlipemia is familial hypercholesterolemia, familial mixing hyperlipemia, reduction or shortage property lipoprotein lipid
Enzyme level or activity, hypertriglyceridemia, hypercholesterolemia, high blood level ketoboidies, high blood level Lp (a) cholesterol, height
Blood level low-density lipoprotein (LDL) cholesterol, high blood level very low density lipoprotein (VLDL) cholesterol or high blood level are non-ester
Change fatty acid.
The disclosure of invention effectively treats or prevents the dyslipoproteinemia by giving further to one kind
Amount Chardonnay seed products treat or prevent mammal in dyslipoproteinemia method.In certain aspects, institute
Stating dyslipoproteinemia is high blood level LDL, high blood level apolipoprotein B (apo B), high blood level Lp (a), high blood level
Apo (a), high blood level VLDL, low blood level HDL, reduction or shortage property lipoprotein lipase levels or activity, low alpha lipoprotein blood
Disease, lipoprotein abnormalities relevant to diabetes, with obesity-related lipoprotein abnormalities, rouge egg relevant with alzheimer's disease
Bai Yichang or familial mix hyperlipemia.
The disclosure of invention effectively treats or prevents mammal by giving to mammal further to one kind
Method of the Chardonnay seed products of the amount of middle metabolism obstacles of blood glucose disease to treat or prevent metabolism obstacles of blood glucose disease in mammal.In
In some aspects, the metabolism obstacles of blood glucose disease is impaired glucose tolerance, insulin resistance (insulin resistance), pancreas islet
Plain tolerance correlation breast cancer, colon cancer or prostate cancer, diabetes, pancreatitis, hypertension, polycystic ovary disease, high-level blood pancreas
Island element or high-level blood glucose.In certain aspects, the diabetes are Non-Insulin Dependent Diabetes Mellitus (NIDDM), pancreas islet
Plain dependent diabetes (IDDM), gestational diabetes (GDM) or maturity onset diabetes of the young (MODY, maturity onset
diabetes of the young)。
The disclosure of invention effectively treats or prevents mammal by giving to mammal further to one kind
Method of the Chardonnay seed products of the amount of middle metabolic syndrome to treat or prevent metabolic syndrome in mammal.
In certain aspects, the amount given effectively adjusts one or more participation fat, cholesterol and/or Bile metabolism
Gene expression.In a specific embodiment, the amount effectively improves the expression of ACOX1 in hepatic tissue, improves in hepatic tissue
The expression of CYP51 improves the expression of CYP7al in hepatic tissue, reduces the expression of SCD1 in hepatic tissue, and/or reduce in hepatic tissue
The expression of ABCG5, for example, at least 10%, at least 20%, at least 50% or at least 100%.
The disclosure of invention effectively improves the mammal intestine by giving to mammal further to one kind
The Chardonnay seed products of the amount of clostridium (Clostridium) amount of bacteria in road are to improve Clostridial bacteria in mammalian gut
The method of amount.
The disclosure of invention effectively improves the mammal intestine by giving to mammal further to one kind
The Chardonnay seed products of the amount of enterobacteria (Enterobacteriaceae) amount of bacteria in road are to reduce mammalian gut
The method of middle Enterobacteriaceae amount.
By giving to the mammal, to effectively improve the lactation dynamic further to one kind for the disclosure of invention
The Chardonnay seed products of the amount of bacteroides fragilis (Bacteroides fragilis) group (group) amount of bacteria in object enteron aisle
Method to improve bacteroides fragilis group amount of bacteria in mammalian gut.
The disclosure of invention effectively treats or prevents lactate acid by giving to mammal further to one kind
Method of the Chardonnay seed products of the amount of poisoning to treat or prevent lactic acidosis in mammal.
In the certain embodiments of these methods, it is not the of Chardonnay seed products that Xiang Suoshu mammal, which is given,
Two grape seeds or grape skin product.In certain aspects, Chardonnay seed products and the second grape seed or grape skin product
The curative effect that provides of combination or health benefits be more than individually to give the effects of Chardonnay seed products.
In certain aspects, the Chardonnay seed products are by having at least 600mg epicatechin/100g seed table
Catechin content or the preparation of the seed of at least 700mg epicatechin/100g seed epicatechin content.In specific embodiment
In, the epicatechin content range is 600-800mg/100g seed or 650-800mg/100g seed.
In some embodiments, the Chardonnay seed products introduce food or beverage products.
In some embodiments, the Chardonnay seed products are Chardonnay seed meals.In some embodiments, institute
Stating Chardonnay seed products is Chardonnay seed extract.In some embodiments, the Chardonnay seed products come spontaneous
The grape being longer than in Winkler (Winkler) local climate I, II, III or IV type.
In some embodiments, the mammal is domestic pets, for example, cat or dog.In the other of these methods
In embodiment, the mammal is the mankind.In other embodiments, the mankind are babies.
The disclosure of invention is further to a kind of infant formula product (infant comprising Chardonnay seed products
Formula) and using the infant formula product promote the method for baby intestinal microbiologic population development.In certain aspects,
The infant formula product promotes intestinal microbiota to develop when giving baby by adjusting the level of enteric bacteria
(development).In some embodiments, the baby passes through cesarean section delivery.In some embodiments, the baby
Youngster is that formulation is fed.
3. Detailed description of the invention
Fig. 1: Chardonnay (Chr), solution hundred patch up (Cabernet Sauvignon) (Cab) and hila (Syrah) (Syr) seed (Sd) and skin
(Sk) albumen, fat, ash content, carbohydrate and total dietary fiber.
Fig. 2: the diet composition of hamster in embodiment 1.
Fig. 3: seed feeding weight of the animal in terms of week in embodiment 1.
Fig. 4: skin feeding weight of the animal in terms of week in embodiment 1.
Fig. 5: the food intake weekly of the animal of embodiment 1.
Fig. 6: the total food intake of the animal of embodiment 1.
Fig. 7: the total amount of heat intake of the animal of embodiment 1.
Fig. 8: plasma lipoprotein cholesterol levels of the animal of embodiment 1 at the end of surrounding.
Fig. 9: blood glucose level of the animal of embodiment 1 at the end of surrounding.
Figure 10: organ weight of the animal of embodiment 1 at the end of surrounding.
Figure 11: epicatechin is horizontal in the seed and skin of different grape varieties.
Figure 12: embodiment 2 includes the body of the animal of the feeding diet of 3wt%, 7wt% and 10wt% Chardonnay seed meal
Weight, weight gain and total food intake.
Figure 13: 2 feeding Chardonnay seed ethanol extract (40EtChrSdEx) of embodiment, Chardonnay seed methanol extract
Object (MeChrSdEx), Chardonnay seed ethyl alcohol extraction residue (40EtChrSdRes), Chardonnay seed methanolic extract are residual
Excess (MeChrSdRes), 10%, 7% and 3% (respectively 10%ChrSd, 7%ChrSd and 3% according to diet weight
ChrSd White Riesling (White Riesling) seed meal (10%WRSd) of Chardonnay seed meal, 10% diet weight)
With the animal of Sauvignon Blanc (Sauvignon Blanc) seed meal (10%SBSd) of 10% diet weight at the end of surrounding
VLDL, LDL and HDL cholesterol levels.
Figure 14: 2 feeding Chardonnay seed ethanol extract (40EtChrSdEx) of embodiment, Chardonnay seed methanol extract
Object (MeChrSdEx), Chardonnay seed ethanol extract residue (40EtChrSdRes), Chardonnay seed methanolic extract
Residue (MeChrSdRes), 10%, 7% and 3% diet weight (respectively 10%ChrSd, 7%ChrSd and 3%ChrSd)
Chardonnay seed meal, White Riesling (White Riesling) seed meal (10%WRSd) and 10% of 10% diet weight
LDL/HDL of the animal of Sauvignon Blanc (Sauvignon Blanc) seed meal (10%SBSd) of diet weight at the end of surrounding
Cholesterol ratio.
Figure 15: 2 feeding Chardonnay seed ethanol extract (40EtChrSdEx) of embodiment, Chardonnay seed methanol extract
Object (MeChrSdEx), Chardonnay seed ethanol extract residue (40EtChrSdRes), Chardonnay seed methanolic extract
The diet weight of residue (MeChrSdRes), 10%, 7% and 3% (respectively 10%ChrSd, 7%ChrSd and 3%ChrSd)
Chardonnay seed meal, White Riesling (White Riesling) seed meal (10%WRSd) and 10% of 10% diet weight
Liver of the animal of Sauvignon Blanc (Sauvignon Blanc) seed meal (10%SBSd) of diet weight at the end of surrounding, epididymis
Fatty (EA) and retroperitoneal fat (RA) weight.
Figure 16: the relatively fatty gene expression of embodiment 3.
Figure 17: the opposite liver gene expression of embodiment 3.
Figure 18: 4 feeding of embodiment supplement Chardonnay seed meal (CharSdFl),Grape seed extract
(VC1 and VC7), MegaBP grape seed extract (BP1, BP7),Grape seed extracts
Total plasma lipoprotein of the animal of the diet of object (L1, L7), catechin (Cat) and epicatechin (EpiCat) at the end of surrounding
Cholesterol levels.
Figure 19: 4 feeding of embodiment supplement Chardonnay seed meal (CharSdFl),Grape seed extract
(VC1 and VC7), MegaBP grape seed extract (BP1, BP7),Grape seed extracts
The animal of the diet of object (L1, L7), catechin (Cat) and epicatechin (EpiCat) VLDL, LDL at the end of surrounding and
HDL cholesterol levels.
Figure 20: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
Total fecal bacteria of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF) is horizontal.
Figure 21: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
The enterococcus spp of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF)
(Enterococcus spp.) is horizontal.
Figure 22: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
The Bifidobacterium of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF)
(Bifidobacterium spp.) is horizontal.
Figure 23: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
The Lactobacillus of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF)
(Lactobacillus spp.) is horizontal.
Figure 24: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
IV groups of bacteria levels of clostridium of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF).
Figure 25: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
The bacteroides fragilis group (group) of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF)
Bacteria levels.
Figure 26: 5 feeding control diet of embodiment, supplement solution hundred patch up the high fat diet of seed meal (RGF+HF), supplement rosy clouds
The enterobacteria of the animal of the high fat diet and high-fat control diet (HF) of Dolly seed meal (WGF+HF) is horizontal.
4. specific embodiment
4.1.Chardonnay seed products
Obesity and other diseases are treated or prevented the present invention relates to Chardonnay seed products and using Chardonnay seed products
The method of disease.It is preferred that the Chardonnay seed products are raw by the grape for being grown on Winkler (Winkler) local climate I-IV type
It produces (Jones et al, 2010, Am.J.Enol.Vitic.61 (3): 313-326).In some embodiments, the rosy clouds are more
Beautiful seed products are by being grown on north plus the coastal mountain valley Li Fuliya, for example, receiving the pa mountain valley (Napa) and/or Suo Nuoma (Sonoma)
The grape in mountain valley produces.In another embodiment, the Chardonnay seed products are by being grown on other hotter inland mountain valleys
Vineyard, for example, the grape of Winkler (Winkler) local climate IV-V type produces.In a preferred embodiment, described
Chardonnay seed products are from the grape being grown in coastal area.
In one embodiment, the Chardonnay seed products contain the non-fat portion of Chardonnay seed, such as Chardonnay
Pomace coarse powder (grits, meal), Chardonnay pomace powder (fine powder, flour), Chardonnay seed meal, or most preferably, Chardonnay
Seed meal (fine powder, fine grinding powder, flour).In some embodiments, the Chardonnay seed products include to pass through organic solvent
It is not extractible, for example, passing through ethyl alcohol and/or the content (content) of the not extractible degreasing Chardonnay seed of methanol.In
In some aspects, the Chardonnay seed products are by epicatechin content at least 600mg epicatechin/100g seed or table catechu
The preparation of cellulose content at least 700mg epicatechin/100g seed seed.In a specific embodiment, the epicatechin content
Range is 600-800mg/100g seed or 650-800mg/100g seed.
As utilized herein, " Chardonnay seed meal " is ground entire seed and " Chardonnay seed meal (Chardonnay
Seed fine powder) " it is grinding seed after extract oil.Chardonnay seed meal can be used known in the art from seed extract oil
It generates " cold pressing ", " hot pressing " or the solvent extraction process of defatted seed powder and obtains.Coarse powder or powder can be by using suitable
The conventional drying technique of dried foods product is dried until moisture content needed for (acquisition).
The coarse powder or powder of the drying further grind under ambient temperature conditions and are formed with free-flowing particle
Chardonnay seed powder.In one embodiment, the particle that flows freely can be the size no more than 841 μm (20 mesh)
To the size for being no more than 37 μm (400 mesh).In some embodiments, the size be no more than 20 mesh, 40 mesh, 60 mesh, 80 mesh,
100 mesh, 200 mesh, 300 mesh or 400 mesh.
In a kind of illustrative methods, Chardonnay seed meal is by separation and dry shrimps and crabs seed, for example, by rosy clouds
The squeezing of Dolly grape is made at the pomace generated after grape juice (for example, grape wine is made).The grape seed can
" cold press " and by its degreasing (Chardonnay seed oil of the production as byproduct).Grape seed powder is carried out by the press cake after oil extraction
Grinding.In an embodiment, the seed is separated from Grape Skin after grape extraction juice, through over cleaning, mechanical degreasing,
Fine gtinding and the flowable powder for sieving and generating 100 mesh (150 μm).
Chardonnay seed meal also can be from Apres Vin (Yakima, Washington), Botanical Oil
Innovations (Spooner, the state of Wisconsin) or Fruitsmart, Inc. (Grandview, Washington) are commercially available.It is described
FruitSmart Chardonnay seed meal is the flowable powder of 85 mesh, but further can grind and sieve and generate with smaller
The powder of particle size.
In one embodiment, skin, stem and leaf (rest part of pomace) are removed from seed before squeezing.It removes
Skin, stem and leaf allow to carry out optimal oil expression.
" Chardonnay seed extract " passes through solvent extraction Chardonnay seed such as ethyl alcohol or methanol using suitable solvent
And it is made.For example, " 40EtChrSdEx " is that 40% ethanol solution is used to extract as Chardonnay seed made of Extraction solvent
Object.The extracting method can also generate the residual of insoluble solid other than the extract containing the Solvent soluble components
Excess.
4.2.Effective quantity
In the embodiment of the method for the invention, percentage specific consumption of the Chardonnay seed meal as day diet
Amount is at least 3%, at least 5% or at least 8% in mass.It is preferred that 5%-10%, more preferable 7%, and in some embodiments
In 10% day diet in mass be Chardonnay seed meal.
In the embodiment of the method for the invention, percentage specific consumption of the Chardonnay seed meal as day diet
The heat (calorie) for the wastage in bulk or weight that amount is at least 3%, at least 5%, or at least 8%.It is preferred that 5%-10%, more preferable 7%, and
The 10% day heat comes from Chardonnay seed meal in some embodiments.
In another embodiment, the amount of the Chardonnay seed meal of daily consumption is at least 10g, at least 15g, at least 20g,
At least 25g, at least 30g, at least 35g, at least 40g, or at least 45g.It is preferred that every daily consumption 50g Chardonnay seed meal.
In another embodiment, the amount of the Chardonnay seed meal of every daily consumption is at least 1 soupspoon, at least 2 soupspoons, at least
3 soupspoons, at least 4 soupspoons, or at least 5 soupspoons.
In another embodiment, the amount of the Chardonnay seed meal of daily consumption is based on Chardonnay seed meal weight: weight is
At least 0.2g/kg, at least 0.5g/kg, or at least 0.7g/kg.It is preferred that consuming at least 1g Chardonnay seed meal/kg weight daily.
In certain aspects, the amount for giving Chardonnay seed meal effectively adjusts one or more participations fat, cholesterol,
And/or the expression of the gene of Bile metabolism.In a specific embodiment, the amount effectively improves the expression of ACOX1 in hepatic tissue,
The expression of CYP51 in hepatic tissue is improved, the expression of CYP7al in hepatic tissue is improved, reduces the expression of SCD1 in hepatic tissue, and/or
The expression of ABCG5 in hepatic tissue is reduced, for example, at least 10%, at least 20%, at least 50%, or at least 100%.
Chardonnay seed meal can be extracted with Chardonnay pomace coarse powder, pomace powder, Pi Fen, seed in the method for the invention
Object or seed meal replace.Chardonnay pomace coarse powder, pomace powder, Pi Fen, seed extract or the consumption of seed meal daily requirement
And the amount for reaching specified rate Chardonnay seed meal same benefits can be readily determined by those skilled in the art in the art.Example
Such as, it is contemplated that needs are consumed the identical benefit that about three times Chardonnay skin powder can be only achieved the Chardonnay seed meal of specified rate by subject
Place.
In some embodiments, the Chardonnay seed products, for example, Chardonnay seed meal, takes at least one week two
It is secondary, at least three times a week, or once every other day.It is preferred that the Chardonnay seed products are introduced into the day diet.
The Chardonnay seed products, for example, the time quantum that Chardonnay seed meal is taken be enough to treat and/or prevent it is suitable
From the illness for the treatment of and/or prevention in Chardonnay seed products as described herein.The Chardonnay seed products can take
With at least one week, at least 2 weeks, at least 3 weeks, at least one moon, at least two moon, at least three moon, at least six moon, at least a year,
Or indefinite duration (indefinitely) takes.
In the certain embodiments of these methods, it is not the second of Chardonnay seed products that Xiang Suoshu mammal, which is given,
Grape seed or grape skin product.In certain aspects, Chardonnay seed products and the second grape seed or grape skin product
The curative effect provided is provided or health benefits have been more than individually to give the effect of Chardonnay seed products.
In other embodiments, the amount of Chardonnay seed products and the amount of the second grape seed or grape skin product are through selecting
It selects and to be allowed to effect obtained at least identical as by individually giving the Chardonnay seed products effect achieved of specified rate.
4.3.Chardonnay seed composition
The Chardonnay seed products can be contained in various food products, if nutritious drink is (for example, nutrition milk shake
(nutritional shakes)), bakery (for example, small biscuit, Brownie, cake, bread, biscuit, crispbread), cloth
Fourth, candy (e.g., preserved fruit), snack food (for example, muffin), ice cream, parfait and novelty (novelties) or non-
Bake ertruding food product product such as stick, including health or energy stick.The Chardonnay seed products can be used as nutritional supplement,
Or it provides in form of tablets or as the powder for being suitable as nutraceutical additive.
In one embodiment, the Chardonnay seed products can be blended with other dry food materials and are used to prepare
Food product rich in Chardonnay seed products.Dry food material includes, for example, dry starch-containing material, dry material containing albumen
Material or combinations thereof.Suitable starch-containing material can be derived from, for example, rice, corn, soybean, sunflower, rape (rape,
Canola), wheat, oat, rye, potato, or any combination thereof.It is suitably dry to be may originate from containing protein material for example, meat,
Milk, fish or any combination thereof.It is applied for baking, the Chardonnay seed products are suitble to the amount ranges used to be 3%~5%
Dry food material (for example, white or wholemeal).The dry food can also optionally include other ingredient such as vitamin,
Mineral-supplemented dose, salt, colorant, flavoring agent, flavoring agent or sweetener.
Chardonnay seed products can be introduced into beverage, processing meat product, frozen dessert, confectionary products, dairy-type product, sauce
In composition and bread basket.Beverage products include, for example, Sorbet (smoothies), infant formula product, fruit drink,
Boruga, coffee beverage, beer, dry beverage mixture, tea merge beverage (tea fusion beverages), movement drink
Material, soy sauce (soy liquor), carbonated drink, sludge ice (slushes) and frozen drink mixes.Meat products include, for example, grinding
Chicken meat product, adds extreme misery leg product, boulogna sausage, hot dog, Frank (franks), chicken patties, chicken nugget (chicken nugget),
Minced beef cutlet, fish cake, minced fillet, bacon, pork luncheon meat, sandwich fillings, cooked meat product (deli meat), jerky based food, meat
Ball, jerky (jerky), beef item (fajitas), Baconic's piece (bacon bits) inject meat and German-style sausage.Confectionary products
Including, for example, chocolate, mousse, chocolate coating, Yoghourt coating, cocoa power, frosting (frosting), toffee, energy stick and
Loaf sugar (candy bar).Frozen dessert class product includes, for example, ice cream, maltose (malt), milk shake (shakes), ice
Rod, ice cream and freezing pudding product.Dairy-type product includes, for example, Yoghourt, cheese, ice cream spray cream (whipped
Topping), coffee cream, cream cheese, Yoghourt, white spirit junket (cottage cheese), butter, mayonnaise
(mayonnaise), milk base sauce, newborn base mayonnaise and cheese curd.Bread basket includes, for example, bread, muffin, hundred
Lucky cake, noodles, biscuit, thin pancake, Waffle, rusk, semolina, French fries, corn-dodger, cake, crispbread are early
It eats cereal (including instant and cooked cereal), pretzels, rusk mixture, melbatoast, stick bread, frying
Bread, fillings, energy stick, baked donut, cake, puffed rice, maize roll, fried covering layer, batter wrap up in powder, crisp skin, chocolate cake
Cake, pie, extruding soya-bean cake can beautiful cake, croissant, powder and maize gruel.Sauce composition includes mayonnaise, and nut butter is smeared
Sauce (for example, peanut butter spread), thick gravy, sauce, salsa this, jam, cheese spread, mayonnaise, sauce, fermented bean curd,
Dip in sauce, fruit sugar syrups and maple syrup (maple syrup).Sauce composition can also include that auxiliary maintains the outstanding of composition homogeneity
Floating auxiliary agent (suspending agent).The example of suitable suspension aids includes polysaccharide, such as starch, cellulose (for example, microcrystalline cellulose) and
Carrageenan and polyuronide, such as pectin.Gelatin is another suspension aids example, it can also be used for beverage composition for treating dental erosion.Root
The example of the additional supplement product prepared according to the present invention using pre-composition includes bean curd, prepares soybean essence, and powdered protein is mended
Fill agent, fruit juice can mixed protein replenishers, foaming agent, clouding agent (clouding agent), baby food, vegetarian diet ball, meat
Like object, egg product (for example, scrambled eggs), soup, chowder (chowder), meat soup, milk substitute, soya milk product, capsicum, fragrance is mixed
Object is closed, sugar is spilt, fermented soya bean (soy whiz), salad topping, edible film, edible bar, chewing gum, Baconic's piece, vegetables volume, Piza
Cake skin barrier layer (pizza crust barriers), soybean pie, no gas synthesize bean curd, bean product helper (soy
Helper), soybean cotton candy (soy cotton candy), fruit fourth, pizza roll, mashed potatoes spin soybean fiber, beans
Volume squeezes out snack (extruded snack), flavouring, lotion, fry (fries), gelatin dessert product, and vitamin is mended
Fill agent, nutrition bar, dry cake, bread or muffin mix and can microwave wink dry mixture (microwavable instant dry
mixes)。
In In a specific aspect, the Chardonnay seed products can be used as energy stick (be suitble to physiological activity consumption) or
Generation meal stick.The energy stick can also contain one or more of vitamin, minerals, food supplement, plant for meal stick
Product (botanical) or plant or herb extract or known in the art or energy stick or for meal stick used at
Point, such as fruit juice or extract, herbal medicine (herb) or odoriferous herbs (herb flavor), natural or artificial flavors, vitamin, mine
Substance, the extract containing antioxidant, ubiquinone, omega-fatty acid, Guarana, caffeine, theobromine, maltodextrin and
Albumen.In some embodiments, the energy stick or for meal stick can have respectively 40/30/30 carbohydrate/egg
Total utilisable energy of white/fat is horizontal.
The energy and the raising for locomitivity can be further supplemented for meal stick, mental capacity or cognition emphasis are strong
Change and/or nutritional benefits.Exemplary replenishers include, but are not limited to vinpocetine, pervone ginkgo leaf essence (Vincamine
Ginkgo Biloba), L-arginine, acetyl-L-carnitine, feverfen (Feverfew), DMAE (dimethylaminoethanol), DMAE
Biatrate, acetic acid parachlorophenol ester, vitamin B complexing agent, ginseng, 5HTP (5-hydroxyryptophan), L-thiamine, androstene two
Ketone, L-Glutamine, l-tyrosine, L- glycine;L-lysine;Lactalbumin;DHEA (dehydroepiandros-sterone).
In another aspect, the Chardonnay seed products can be provided in or be added to liquid or powder infant formula
In product.The infant formula product can contain protein sources, fat source and/or carbohydrate source.The protein sources can
It is, for example, dry or liquid milk, whey and/or casein or soybean protein.The fat source can be, for example, dairy products
Fatty and/or one or more vegetable oil.The carbohydrate source can be, for example, lactose, glucose or sucrose.It is described
In addition infant formula product can contain one or more vitamins and/or one or more minerals.In an embodiment
In, the Chardonnay seed products can be added in commercially available liquid or powder infant formula product.
The Chardonnay seed composition also can containing one measure be not Chardonnay seed products the second grape kind
Son or grape skin product.In some embodiments, the Chardonnay seed products of an amount are in the Chardonnay seed group
Close the second grape seed and Grape Skin products substitution measured in object with one.It needs to be added in the Chardonnay seed composition
It can be held very much with acquisition and the second grape seed of Chardonnay seed products same benefits or the amount of grape skin product of specified rate
It changes places and is determined by those skilled in the art.
4.4.The therapeutical uses of Chardonnay seed compound powder
According to the present invention, composition of the invention includes Chardonnay seed compound powder, to subject, preferably to the mankind
Subject gives, and lipid-metabolism increase is useful or desired in the subject.The subject may need
Treatment or prevention cardiovascular disease, dyslipidemia, impaired glucose metabolism, Alzheimer's disease, X syndrome, PPAR are related
Disfunction, septicemia, thrombus sexual disfunction (thrombotic disorder), obesity, pancreatitis, hypertension, kidney
Disease, cancer, inflammation or impotence.
In another aspect of the present invention, composition of the invention includes Chardonnay seed compound powder, to tested
Person preferably gives to human experimenter, and the biocenological adjusting of the enteron aisle described in the subject is useful or expectation
's.In one embodiment, the subject may need to treat or prevent, for example, lactic acidosis, colitis, or
Colorectal cancer.In one embodiment, the subject is that heredity is susceptible to suffer from colon cancer.
In one embodiment, " treatment ", which refers to, improves a kind of disease or illness or its at least one recognizable disease
Shape.In another embodiment, " treatment " refers to that improving at least one might not be joined by the recognizable measurable physiology of main body
Number.In another embodiment, " treatment " refers to the progress for inhibiting disease or illness, either physically, for example, can distinguish
The stabilization of symptom, physiologically, for example, the stabilization of physiological parameter, or both have both at the same time.In an embodiment also
In, " treatment " refers to the breaking-out for delaying disease or illness.
In some embodiments, composition of the invention gives subject, the preferably mankind, as to the pre- of these diseases
Anti- property measure.As utilized herein, " prevention " or " preventing ", which refers to, reduces the risk for obtaining given disease or illness.It is excellent at one
In the aspect of choosing, the present composition gives subject as precautionary measures, and preferably to cardiovascular disease, dyslipidemia is different
Normal lipoproteinemia, impaired glucose metabolism disease, Alzheimer's disease, X syndrome, the related dysfunction disease of PPAR are lost
Mass formed by blood stasis, thrombus sexual disfunction, obesity, pancreatitis, hypertension, nephrosis, cancer, inflammation or impotence have inheritance susceptible
The mankind of property.The example of this genetic predisposition includes but is not limited to the E4 allele of apo E, will increase alzheimer '
A possibility that silent disease;Afunction or null mutation are (for example, causing to replace in lipoprotein lipase gene coding region or promoter
For the mutation in the code area of D9N and N291S;Review will increase cardiovascular disease, dyslipidemia and dyslipoproteinemia wind
Gene mutation in the lipoprotein lipase gene of danger, referring to Hayden and Ma, 1992, Mol.Cell Biochem.113:
171-176);Hyperlipemia and familial hypercholesterolemia are mixed with familial.
In another preference pattern of the embodiment, composition of the invention as precautionary measures give have pair
Cardiovascular disease, dyslipidemia, dyslipoproteinemia, glucose metabolism disorders, Alzheimer's disease, X syndrome, PPAR
Related dysfunction disease, septicemia, thrombus sexual disfunction, obesity, pancreatitis, hypertension, nephrosis, cancer, inflammation
Or the subject of the non-genetic predisposition of impotence.The example of this non-genetic predisposition includes but is not limited to: bypass surgery
With percutaneous transluminal coronary angioplasty (percutaneous transluminal coronary angioplasty), this is past
It is past to will lead to restenosis, the acceleration form of atherosclerosis;Diabetes in women, this frequently can lead to polycystic ovary
Disease;And cardiovascular disease, this frequently can lead to impotence.
In some embodiments, the mammal consumes high fat diet.In one embodiment, high-fat drink
Food is that wherein at least 30%, 35% or 40% total day heat is obtained from the diet of fat.
In some embodiments, the second grape seed or grape skin product of non-Chardonnay seed meal are dynamic to the lactation
It is more than the effect for individually giving Chardonnay seed meal effect that object, which is given and provided,.
4.4.1.Dyslipidemia
The present invention provides the methods for treating or preventing dyslipidemia, including give therapeutically effective amount to subject
Chardonnay seed compound powder.
The term as used herein " dyslipidemia " refers to the disfunction for leading to or showing the circulation lipid of abnormal level.Blood
Lipid level is excessively high to a certain extent in liquid, and composition of the invention gives subject and restores normal level.Lipid it is normal
Level report is in medicine treatise well known by persons skilled in the art.For example, LDL, HDL, three ester of dissociative glycerin and other and rouge
The recommendation blood level that matter is metabolized relevant parameter can be ground in the website of American Heart Association and national heart, lung and blood
Study carefully the website of National Cholesterol Education Program find.Currently, the recommended levels of HDL cholesterol in blood are higher than
35mg/dL;The recommended levels of LDL cholesterol in blood are lower than 130mg/dL;The LDL:HDL cholesterol ratio recommended in blood
Lower than 5:1, ideally 3.5:1;And the recommended levels of three ester of dissociative glycerin in blood are less than 200mg/dL.
The dyslipidemia that Chardonnay seed compound powder of the invention is suitable for treating or preventing includes but is not limited to height
Blood lipid disease and low blood level high-density lipoprotein (HDL) cholesterol.In some embodiments, compound prevention through the invention
Or the hyperlipemia for the treatment of is familial hypercholesterolemia;Familial mixes hyperlipemia;Reduction or shortage property lipoprotein lipid
Enzyme level or activity, including the reduction or shortage caused by lipoprotein lipase mutations;Hypertriglyceridemia;Hypercholesteremia
Disease;High blood level ketoboidies (such as β-OH butyric acid);High blood level Lp (a) cholesterol;High blood level low-density lipoprotein (LDL) gallbladder is solid
Alcohol;High blood level very low density lipoprotein (VLDL) cholesterol and high blood level non-esterified fatty acid.
Invention further provides lipid-metabolism in subject is changed, for example, reducing LDL in subject's blood, reduce
In subject's blood dissociate triglycerides, increase subject's blood in HDL/LDL ratio, and inhibit saponification and/or
Non-saponified fatty acid synthetic method, the method includes the rosy clouds for giving the amount for effectively changing lipid-metabolism to the subject are more
Beautiful seed compound powder.
4.4.2.Cardiovascular disease
The present invention provides the methods for treating or preventing cardiovascular disease, including giving therapeutically effective amount to subject
Chardonnay seed compound powder.The term as used herein " cardiovascular disease " refers to the disease of heart and the circulatory system.These diseases
It is often related with dyslipoproteinemia and/or dyslipidemia.The present composition is suitable for the angiocarpy for preventing or treating
Disease includes but is not limited to arteriosclerosis;Atherosclerosis;Apoplexy;Ischemic;Endothelial dysfunction disease, especially those shadows
Ring the dysfunction of blood vessel elasticity;Peripheral artery disease;Coronary heart disease;Myocardial infarction;Cerebral infarction and restenosis.
4.4.3.Dyslipoproteinemia
The present invention provides the methods for treating or preventing dyslipoproteinemia, including give treatment to subject and have
The Chardonnay seed compound powder of effect amount.
The term as used herein " dyslipoproteinemia " refers to the blood circulation lipoprotein for leading to or showing as abnormal level
Disfunction.Lipoprotein levels are crossed up to a certain degree in blood, and composition of the invention gives subject and restores normal water
It is flat.On the contrary, lipoprotein levels are crossed down to a certain degree in blood, composition of the invention gives subject and restores normal water
It is flat.The normal level of lipoprotein is reported in medicine treatise known to those skilled in the art.
The dyslipoproteinemia that the present composition is suitable for preventing or treating includes but is not limited to high blood level LDL;
High blood level apolipoprotein B (apo B);High blood level Lp (a);High blood level apo (a);High blood level VLDL;Low blood level
HDL;Reduction or shortage property lipoprotein lipase levels or activity, including the reduction or shortage caused by lipoprotein lipase mutations;Low α
Lipoproteinemia;Lipoprotein abnormalities relevant to diabetes;With obesity-related lipoprotein abnormalities;With alzheimer's disease phase
The lipoprotein abnormalities of pass;Hyperlipemia is mixed with familial.
The present invention also provides reducing, apo C-II in subject's blood is horizontal;Reduce subject's blood apo C-III water
It is flat;Promoted HDL GAP-associated protein GAP level, including but not limited to apo A-I, apo A-I1, the apo A-IV of subject's blood and
apo E;It improves the level of the apo E of subject's blood and promotes the method for removing triglycerides from subject's blood, it is described
Method includes giving effectively to generate the reduction respectively to the subject, the Chardonnay seed compound powder for improving or promoting.
4.4.4.Metabolism obstacles of blood glucose disease
The present invention provides the methods for treating or preventing metabolism obstacles of blood glucose disease, including giving therapeutically effective amount to subject
Chardonnay seed compound powder.The term as used herein " metabolism obstacles of blood glucose disease ", which refers to, leads to or shows as aberrant glucose storage
And/or the illness utilized.Glucose metabolism mark (that is, blood insulin, blood glucose) is excessively high to a certain extent, composition of the invention
It gives subject and restores normal level.On the contrary, the mark of glucose metabolism is crossed down to a certain degree, composition of the invention is given
It gives subject and restores normal level.The normal mark of glucose metabolism is reported in medicine treatise well known by persons skilled in the art
In.
The metabolism obstacles of blood glucose disease that the present composition is suitable for preventing or treating includes but is not limited to that impaired glucose is resistance to
By property;Insulin resistance;The relevant breast cancer of insulin resistance, colon cancer or prostate cancer;Diabetes, including but not limited to
Non-Insulin Dependent Diabetes Mellitus (NIDDM), insulin-dependent diabetes mellitus (IDDM), gestational diabetes (GDM) and youth
Late-stage diabetic (MODY);Pancreatitis;Hypertension;Polycystic ovary disease;With high-level blood insulin and/or hyperglycemia.
Invention further provides change subject in glycometabolism, for example, improve subject insulin sensitivity and/
Or the method for oxygen consumption, the method includes the Chardonnay seed meal combination for the amount for effectively changing glycometabolism is given to the subject
Object.
4.4.5.The adjusting of enteric bacteria
People enteron aisle biocoene is divided into three quasi-microorganism partings according to the species of the bacterial community dominance.This is slightly
Biological typing is bacteroid, Ruminococcus and melaninogenicus.It is found that the bacteroid microorganism parting can prepare several
Vitamin, including C and H, and simultaneously it is found that the Prevost bacteria microorganism parting can prepare folic acid and vitamin B1.
The present invention provides the methods for adjusting enteric bacteria level, including give to subject and effectively adjust enteric bacteria water
The Chardonnay seed compound powder of flat amount.As utilized herein, " it is horizontal to adjust enteric bacteria " and refers to (i) enteric bacteria level
Total amount reduces, and/or the bacteria levels of (ii) total intestinal bacterial subpopulations (subset) increase or decrease.Total intestinal bacterial subpopulations
It can be single species, belong to, section, mesh, guiding principle, door, or the combination of the above more than one.
For example, it is horizontal to adjust intestinal flora in the baby by caesarean deliveries, it may be possible to it is desirable, because described
The bacteria planting of enteron aisle can postpone in the baby of caesarean birth compared to the baby of vaginal delivery.The difference of intestinal flora may be
6 months as long as (Grolund, M.et al, Journal of Pediatric are lasted up to after birth
Gastroentero10gy&Nutrition, (1999), vol.28 (1): 19-25).For example, the baby by caesarean birth compares
The bacterium of significant less bacteroides fragilis group can be colonized when the baby of vaginal delivery birth is in six-month-old.Seven days after birth,
The baby of caesarean birth can have the higher levels of intestines as total enteric bacteria percentage compared to the baby that vaginal delivery is born
Bacillus bacterium citric acid bacillus and Escherichia coli (Pandey, P.et al., J.Biosci. (2012) vol.37 (6): 989-
998).Chardonnay seed compound powder can be used in improving the level of bacteroides fragilis group bacterium and clostridium, and for example reduces and cut open
Abdomen produces the level of enterobacteriaceae lactobacteriaceae in baby and promotes the biocenological formation of enteron aisle, closer to go out similar to vaginal delivery
The intestinal microflora of raw baby.
Chardonnay seed compound powder can also be used to the amount by reducing lactic acid producing bacteria such as Bacillus acidi lactici in enteron aisle
And treat or prevent lactic acidosis.Chardonnay seed compound powder also can be used in the water by improving clostridium in enteron aisle
Health that is flat and promoting colon.Clostridial bacteria generates butyrate, this is preferred energy source in mucous membrane of colon.Butyrate protection knot
Enteritis and colorectal cancer, and the normal development of colon epithelial cell is important.Shen, J.et al., Applied
And Environmental Microbiology, vol.72:5232-5238 (2006).
Chardonnay seed compound powder also can be used in reducing the level of Bifidobacterium in enteron aisle.However, if reducing
The level of Bifidobacterium is undesirable, and when another treatment benefit for giving Chardonnay seed meal is desired, then contain
The Probiotic supplement of one or more bifidobacterium species can give the subject and improve in subject's enteron aisle
The level of bifidobacterium species.The example that the bifidobacterium species in Probiotic supplement can be given includes that Bifidobacterium is double
Discrimination bacillus (Bifidobacterium bifidum), bifidobacterium breve (Bifidobacterium breve) and long bifid
Bacillus (Bifidobacterium longum).The Probiotic supplement can include other bacteria cultures, for example, it is a kind of or
A variety of lactobacillus acidophilus (Lactobacillus acidophilus), lactobacillus plantarum (Lactobacillus
Plantarum), saliva Bacillus acidi lactici (Lactobacillus salivarious), Lactobacillus casei (Lactobacillus
Casei), secondary Lactobacillus casei (Lactobacillus paracasei), Lactobacillus rhamnosus (Lactobacillus
) and streptococcus thermophilus (Streptococcus thermophilus) rhamnosus.
In one embodiment, the subject, which is confirmed as having, belongs to bacteroid, Ruminococcus or Prevost
The microorganism parting of bacterium.In one embodiment, the subject has bacteroid microorganism parting.In an embodiment
In, the subject has Ruminococcus microorganism parting.In one embodiment, the subject has melaninogenicus
Microorganism parting.
4.5.The therapeutical uses of Chardonnay seed extract composition
According to the present invention, composition of the invention includes Chardonnay seed extract composition, gives subject, preferably
Human experimenter, for each therapeutical uses described in Section 4.4.Chardonnay seed extract has the Chardonnay seed
The similar biological effect of powder (data are not shown).In order to realize comparable to the benefit for using a certain amount of Chardonnay seed meal to obtain,
The dosage of Chardonnay seed extract to be administered should be to provide the 2-5 times of catechin level of the Chardonnay seed meal amount
Amount.For obtain daily consumption required for Chardonnay seed meal same benefits with specified rate Chardonnay seed extract it is specific
Amount, can easily be determined by those skilled in the art.
5.Embodiment 1: Chardonnay, Sauvignon Blanc (SAUVIGNON BLANC) and White Riesling (WHITE RIESLING) produce The comparison of product health benefits
5.1.Materials & Methods
5.1.1.Hamster and diet
Male golden Syria hamster (~80g, LVG strain, Charles River) is tamed, and in experimental diet
Water and 5001 rodent diets (LabDiet, PMI International are arbitrarily given before starting;Albumen, 239g/kg;
Fat, 50g/kg;Non-nitrogen containing substance 487g/kg;Crude fibre, 51g/kg;Ash content, 70g/kg;Energy, 17MJ/kg;With for tieing up
Hold the sufficient amount minerals and vitamins of health) up to 1 week.Hamster weighs and is randomly divided into 2 groups, every group of 15 hamsters,
And feeding contains the Chardonnay of 10wt% (by weight), hundred patchwork vestment worn by a Buddhist monk of solution or hila grape seed powder or grape skin powder or control at random
The food rich in fat of (diet) is up to 4 week.The grape growth of the powder is produced in the coastal mountain valley in northern California.The combination of the powder
Object is as shown in Figure 1.Diet is configured to 18% protein energy, 43% carbohydrate energy, and 39% adipose energy (is wherein supplemented with
0.1% cholesterol) (Fig. 2) GenOil, refer to a kind of commercial glucose seed oil from unspecified grape variety.Weight is weekly
Record and the intake of food monitors weekly twice.The research is by animal care and uses the committee (Animal Care and Use
Committee) (Western Regional Research Center, USDA, Albany, CA) ratifies.
5.1.2.Blood plasma and tissue sampling
It hamster fasting 12 hours, is anaesthetized with isoflurane (Phoenix pharmacopeia (Phoenix Pharmaceutical)).With
The syringe rinsed in advance with EDTA potassium solution (15%wt:v) collects blood and at 4 DEG C by cardiac puncture with 2000 × g
Separated plasma after centrifugation 30 minutes.Liver, weighing are collected, and is frozen in liquid nitrogen immediately for analyzing.
5.1.3.Blood plasma biomarker analysis
Cholesterol in plasma lipoprotein is measured (German et as described previously by size exclusion chromatography
Al, 1996.Nutr Res.1996;16:1239-49).Plasma triglyceride, total cholesterol, free cholesterol and glucose are logical
It crosses using Roche Diagnistics/Hitachi 914 clinical analysers (Roche Diagnostics/Hitachi with assay kit
914Clinical Analyzer) (Roche Diagnostics and Wako Chemicals) enzyme colorimetric analysis carry out
Measurement.The adiponectin (B-bridge International) of fasting hamster and the plasma concentration of insulin (Mercodia) use
Foregoing mouse adiponectin and hypersensitive rat insulin immunoassay kit be measured (Hung et al, 2009,
J.Diabetes 1:194-206).Blood sugar concentration in fasting hamster uses OneTouch Ultrameter (LifeScan) In
It is measured in tail vein sample.
5.1.4.Liver lipid analysis
Freeze-drying grinds liver sample using accelerated solvent extractor agent (Dionex) at 100 DEG C;Under 13.8MPa with 75/25 oneself
Alkane/2- propyl alcohol extracts.The sample extraction object is on 914 clinical analysers of Roche Diagnistics/Hitachi (Roche Diagnostics)
It analyzes and uses above-mentioned kit measurement liver triglycerides, total cholesterol and free cholesterol.
5.1.5.Fecal bile acid and sterol analysis
Excrement is collected for three days on end immediately before the hamster slaughter, and is lyophilized, and is ground and is stored at -20 DEG C.Bile
Acid and sterol pass through HPLC and are measured (Hong et al, 2007, J Agric Food Chem.55:9750- as previously described
7)。
5.1.6.Statistical analysis
All data are represented as average value ± SE.Difference between control and different diet groups passes through double tail student t inspections
(2-tailed Student's t test) is tested to be determined.When the variance of each group is not equal, the significance of difference is examined using Webster
(Welch's test) is tested to be determined.It calculates Pearson correlation coefficient and studies total plasma cholesterol, Plasma adiponectin is dense
Relationship (JMP7 statistics program, the SAS software study institute (SAS of degree, liver cholesterol and triglyceride concentration and liver gene expression
Institute)).Conspicuousness is defined as P < 0.05.
5.2.As a result
Compared to the animal of the other diet of feeding, the weight of animals for feeding Chardonnay seed meal significantly reduces (Fig. 3-4).
The animal of feeding Chardonnay seed meal diet just has the average weight of about 97g after 4 week.The animal 4 of fed control diet
With the average weight of about 110g after a week.
Although the Chardonnay seed treated powder the weight of animals is lower than control-animal, the Chardonnay seed treated powder is dynamic
Object eats much (Fig. 5), either according to volume (Fig. 6) or heat (Fig. 7).
The animal of Chardonnay seed meal diet described in feeding shows VLDL (66%) and LDL (50%) cholesterol most
It is big to reduce (Fig. 8).Blood glucose shows slightly to reduce (Fig. 9).
Chardonnay seed meal reduces liver weight and epididymal adipose (EA) weight is respectively 30% and 20% (Figure 10).
These statistics indicate that, Chardonnay seed meal obviously protrudes in the grape product tested.The performance of Chardonnay skin powder
Similar trend out, but benefit does not have Chardonnay seed meal big like that.
6.Embodiment 2: Chardonnay, Sauvignon Blanc (SAUVIGNON BLANC) and White Riesling (WHITE RIESLING) produce The comparison of the health benefits of product
6.1.Materials & Methods
6.1.1.Hamster and diet
Male golden Syria hamster (~80g, LVG strain, Charles River) is tamed, and in experimental diet
Water and 5001 rodent diets (LabDiet, PMI International are given before starting at random;Albumen, 239g/kg;
Fat, 50g/kg;Non-nitrogen containing substance, 487g/kg;Crude fibre, 51g/kg;Ash content, 70g/kg;Energy, 17MJ/kg;Be used for
Maintain the sufficient amount minerals and vitamins of health) it is up to a week.Hamster weighs and is randomly divided into 10 groups, every group 10
Hamster, and the ethanol extract of seed containing Chardonnay is fed at random, Chardonnay seed methanolic extract, Chardonnay seed ethyl alcohol extracts
Residue, Chardonnay seed methanol extract residue, 10% (by weight) Chardonnay seed meal, 10% (by weight) appearance
Think of (Sauvignon Blanc) seed meal, 10% (by weight) White Riesling (White Riesling) seed meal, 7%
(by weight) Chardonnay seed meal, the high fat diet of 3% (by weight) Chardonnay seed meal or control diet are up to 4
A week.The grape growth of the powder is produced in the coastal mountain valley in northern California.Ethanol extract and extraction residue are by the way that " tea extracts
Method " preparation, including the following steps: (1) solvent (ethyl alcohol in 40% distilled water of 1625mL) is added to 325g Chardonnay kind
In sub- powder and in 80 DEG C of vibration 2h;(2) mixture of step (1) then passes through 1 filter paper of Whatman and is filtered;(3) then
Ethyl alcohol is removed from the filtrate of step (2) on the rotary evaporator;(4) solution of step (3) and the filter cake of step (2) respectively into
Row is freezed and is lyophilized and generates Chardonnay seed ethanol extract and Chardonnay seed ethyl alcohol extraction residue.Similar method is used
Residue is extracted in production Chardonnay seed methanolic extract and Chardonnay seed methanol.
Diet is configured to 18% energy as albumen, and 43% energy as carbohydrate, 39% as fat
Energy (is wherein supplemented with 0.1% cholesterol).Weekly record weight and food intake monitor weekly twice.The research is protected by animal
Manage and use the committee (Animal Care and Use Committee) (Western Regional Research
Center, USDA, Albany, CA) approval.
6.1.2.Blood plasma and tissue sampling
It hamster fasting 12 hours, is anaesthetized with isoflurane (Phoenix Pharmaceutical).Using in advance with EDTA potassium
After the syringe that solution (15%wt:v) rinses is collected blood by cardiac puncture and is centrifuged 30 minutes at 4 DEG C with 2000 × g
Separated plasma.Liver, weighing are collected, and is frozen in liquid nitrogen immediately for analyzing.
6.1.3.Blood plasma biomarker analysis
Cholesterol in plasma lipoprotein is measured (German et as described previously by size exclusion chromatography
Al, 1996.Nutr Res.1996;16:1239-49).Plasma triglyceride, total cholesterol, free cholesterol and glucose are logical
It crosses using Roche Diagnistics/Hitachi 914 clinical analysers (Roche Diagnostics/Hitachi with assay kit
914Clinical Analyzer) (Roche Diagnostics and Wako Chemicals) enzyme colorimetric analysis carry out
Measurement.The adiponectin (B-bridge International) of fasting hamster and the plasma concentration of insulin (Mercodia) use
Foregoing mouse adiponectin and hypersensitive mouse insulin immunoassay kit be measured (Hung et al, 2009,
J.Diabetes 1:194-206).Blood sugar concentration in fasting hamster uses OneTouch Ultrameter (LifeScan) In
It is measured in tail vein sample.
6.1.4.Liver lipid analysis
Freeze-drying grinds liver sample using accelerated solvent extractor agent (Dionex) at 100 DEG C;Under 13.8MPa with 75/25 oneself
Alkane/2- propyl alcohol extracts.The sample extraction object is on 914 clinical analysers of Roche Diagnistics/Hitachi (Roche Diagnostics)
It analyzes and uses above-mentioned kit measurement liver triglycerides, total cholesterol and free cholesterol.
6.1.5.Fecal bile acid and sterol analysis
Excrement is collected for three days on end immediately before the hamster slaughter, and is lyophilized, and is ground and is stored at -20 DEG C.Gallbladder
Juice acid and sterol be measured as previously described by HPLC (Hong et al, 2007, J Agric Food Chem.55:
9750-7)。
6.1.6.Statistical analysis
All data are represented as average value ± SE.Difference between control and different diet groups passes through double tail student t inspections
(2-tailed Student's t test) is tested to be determined.When the variance of each group is not equal, the significance of difference is examined using Webster
(Welch's test) is tested to be determined.It calculates Pearson correlation coefficient and studies total plasma cholesterol, Plasma adiponectin is dense
Degree, relationship (JMP7 statistics program, the SAS software study institute (SAS of the expression of liver cholesterol and triglyceride concentration and liver gene
Institute)).Conspicuousness is defined as P < 0.05.
6.2.As a result
The Chardonnay seed meal for accounting for the diet 10wt% shows the reproducible result of embodiment 1.Feeding, which has, accounts for drink
The weight of animals of the diet of the Chardonnay seed meal of food 10wt% has 35% fat diet compared to control-animal minimum
Weight gain.
Chardonnay seed meal shows dosage-response.10%, 7% or 3% Chardonnay seed meal of feeding animal is as its drink
A part of food was up to for 4 week.Observe that response gradually increases, this is designated as the difference of weight;Animal eats more, increases
The weight added is fewer (Figure 12).
Chardonnay seed extract shows to have a certain impact to weight, but be not directly added into Chardonnay seed meal that
Sample is significant.
Chardonnay seed extract and Chardonnay seed extract residue are to cholesterol levels (Figure 13) and LDL/HDL
The ratio between (Figure 14) show certain effect, but it is and significant not as good as being directly added into Chardonnay seed meal.Similarly, the rosy clouds
Dolly seed extract, which is shown, has a certain effect (Figure 15) organ weight, but and is not so good as to be directly added into Chardonnay seed meal
It is significant like that.
Other white seed meals;Such as Sauvignon Blanc (Sauvignon Blanc) or White Riesling (White Riesling)
Weight is shown seldom even without difference compared to the control diet.Chardonnay and other four kinds of kinds (mutation) are one by one
Compare, and obvious outstanding.
7.Embodiment 3: influence of the Chardonnay seed meal to fat relatively and liver gene expression
7.1.Materials & Methods
7.1.1.Hamster and diet
Male golden Syria hamster (~80g, LVG strain, Charles River) is tamed, and in experimental diet
Water and 5001 rodent diets (LabDiet, PMI International are given before starting at random;Albumen, 239g/kg;
Fat, 50g/kg;Non-nitrogen containing substance, 487g/kg;Crude fibre, 51g/kg;Ash content, 70g/kg;Energy, 17MJ/kg;Be used for
Maintain the sufficient amount minerals and vitamins of health) it is up to a week.Hamster weighs and is randomly divided into 2 groups, and feeds at random
It was up to for 4 week containing 10% (by weight) Chardonnay seed meal or control diet.Produce the grape growth Yu Beijia of the powder
The coastal mountain valley in state.Diet is configured to 18% energy as albumen, and 43% energy as carbohydrate, 39% as fat
Energy (being wherein supplemented with 0.1% cholesterol).Weekly record weight and food intake monitor weekly twice.The research is by animal
Nurse and use the committee (Animal Care and Use Committee) (Western Regional Research
Center, USDA, Albany, CA) approval.
7.1.2.MRNA analysis
Quantitative PCR (qPCR) is used to measure the hamster for supplementing diet or control diet from Chardonnay seed meal described in feeding
Fat and liver sample described in inflammation, cholesterol, the mRNA expression of the selected gene of bile acid and fatty acid pathway.
7.1.3.Statistical analysis
All data are expressed as average value ± SD.Shown average value is the supplement diet of Chardonnay seed meal described in feeding
MRNA level in-site is relative to mRNA level in-site in the fat or hepatic tissue of the hamster of feeding control diet in the fat or hepatic tissue of hamster
Relative value.
7.2.As a result
Compare Chardonnay seed meal described in feeding supplement diet hamster adipose tissue in gene expression relative to feed
The relative gene expression level for eating the gene expression in the adipose tissue of the hamster of control diet is as shown in figure 16.Compare feeding institute
State Chardonnay seed meal supplement diet hamster hepatic tissue in gene expression relative to feeding control diet hamster liver
The relative gene expression level of gene expression in tissue is as shown in figure 17.
In the hamster of expression Chardonnay seed meal described in feeding supplement diet of liver ACOX1, CYP51 and CYP7al gene
It is significant to increase, and simultaneously in the hamster of liver ABCG5 and SCD1 gene expression the Chardonnay seed meal described in feeding supplement diet
It is remarkably decreased.
ACOX1 participates in the adjusting of fat oxidation, and CYP51 participates in the adjusting of Biosynthesis of cholesterol, and CYP7al participates in bile
The adjusting of acid synthesis, SCD1 participate in Fatty synthesis, and ABCG5 takes part in cholesterol and returns to transport to enteral.Therefore, the result table
Bright, the diet of supplement Chardonnay seed meal can reduce the re-absorption of cholesterol and/or bile, lead to the horizontal drop in the liver
It is low.The result further demonstrates that the diet for supplementing Chardonnay seed meal can raise fat oxidation by liver gene
(ACOX1) and/or by the downward (SCD1) of Fatty synthesis gain is lost weight.
8.Embodiment 4: Chardonnay seed meal and shrimps and crabs seed extract are in contrast to commercial glucose seed extract Health benefits comparison
8.1.Materials & Methods
8.1.1.Hamster and diet
Male golden Syria hamster (~80g, LVG strain, Charles River) is tamed, and in experimental diet
Water and 5001 rodent diets (LabDiet, PMI International are given before starting at random;Albumen, 239g/kg;
Fat, 50g/kg;Non-nitrogen containing substance, 487g/kg;Crude fibre, 51g/kg;Ash content, 70g/kg;Energy, 17MJ/kg;Be used for
Maintain the sufficient amount minerals and vitamins of health) it is up to a week.All grape seed extracts all pass through HPLC method
It is characterized and its feeding dosage through overregulating provides 7% (w/w) Chardonnay seed meal identical catechin amount.Hamster weighing
And 10 groups are randomly divided into, every group of 8 hamsters, and random feeding includes 7% (by weight) Chardonnay seed meal (1 group),Grape seed extract (2 groups), MegaBP grape seed extract (2 groups),Grape seed extract (2 groups), catechin (about 0.000785g/g diet) (1 group), epicatechin is (about
0.00104g/g diet) (1 group) or (1 group) of control diet was up to for 4 week.Catechin level is used for every kind of grape seed
Extract is standardized into the amount of Chardonnay seed meal.Epicatechin and catechin are included in feed diet as these chemical combination
The control of object, they show to be responsible for blood pressure and lipid regulation in other researchs.The grape for producing the Chardonnay seed meal is raw
It is longer than in northern California seashore mountain valley.Diet include 18% energy as albumen, 43% energy as carbohydrate, 39%
Energy as fat (it is supplemented with 0.1% cholesterol).Weekly record weight and food intake monitor weekly twice.The research
By animal care and use the committee (Animal Care and Use Committee) (Western Regional
Research Center, USDA, Albany, CA) approval.
8.1.2.Blood plasma and tissue sampling
It hamster fasting 12 hours, is anaesthetized with isoflurane (Phoenix Pharmaceutical).Using in advance with EDTA potassium
After the syringe that solution (15%wt:v) rinses is collected blood by cardiac puncture and is centrifuged 30 minutes at 4 DEG C with 2000 × g
Separated plasma.Liver, weighing are collected, and is frozen in liquid nitrogen immediately for analyzing.
8.1.3.Blood plasma biomarker analysis
Cholesterol in plasma lipoprotein is measured (German et as described previously by size exclusion chromatography
Al, 1996.Nutr Res.1996;16:1239-49).Plasma triglyceride, total cholesterol, free cholesterol and glucose are logical
It crosses using Roche Diagnistics/Hitachi 914 clinical analysers (Roche Diagnostics/Hitachi with assay kit
914Clinical Analyzer) (Roche Diagnostics and Wako Chemicals) enzyme colorimetric analysis carry out
Measurement.The adiponectin (B-bridge International) of fasting hamster and the plasma concentration of insulin (Mercodia) use
Foregoing mouse adiponectin and hypersensitive mouse insulin immunoassay kit be measured (Hung et al, 2009,
J.Diabetes 1:194-206).Blood sugar concentration in fasting hamster uses OneTouch Ultrameter (LifeScan) In
It is measured in tail vein sample.
8.1.4.Liver lipid analysis
Freeze-drying grinds liver sample using accelerated solvent extractor agent (Dionex) at 100 DEG C;Under 13.8MPa with 75/25 oneself
Alkane/2- propyl alcohol extracts.The sample extraction object is on 914 clinical analysers of Roche Diagnistics/Hitachi (Roche Diagnostics)
It analyzes and uses above-mentioned kit measurement liver triglycerides, total cholesterol and free cholesterol.
8.1.5.Fecal bile acid and sterol analysis
Excrement is collected for three days on end immediately before the hamster slaughter, and is lyophilized, and is ground and is stored at -20 DEG C.Gallbladder
Juice acid and sterol be measured as previously described by HPLC (Hong et al, 2007, J Agric Food Chem.55:
9750-7)。
8.1.6.Statistical analysis
All data are represented as average value ± SE.Difference between control and different diet groups passes through double tail student t inspections
(2-tailed Student's t test) is tested to be determined.When the variance of each group is not equal, the significance of difference is examined using Webster
(Welch's test) is tested to be determined.It calculates Pearson correlation coefficient and studies total plasma cholesterol, Plasma adiponectin is dense
Relationship (JMP7 statistics program, the SAS software study institute (SAS of degree, liver cholesterol and triglyceride concentration and liver gene expression
Institute)).Conspicuousness is defined as P < 0.05.
8.2.As a result
The total cholesterol and LDL cholesterol blood plasma level for feeding the animal of Chardonnay seed meal are than feeding supplement commercial glucose
The animal of the diet of seed extract significantly reduces (Figure 18-19), but feeding supplementsGrape seed extracts
One in the animal groups of the diet of object (L7) is exception.These statistics indicate that, Chardonnay seed meal is better than all, but for dropping
Except one of low total cholesterol and the business grape seed extract of LDL cholesterol test.
9.Embodiment 5: influence of the Chardonnay seed meal to fecal microorganism level
9.1.Materials & Methods
9.1.1.Fecal specimens
In the 0th day (control) He, (diet of Chardonnay seed meal supplement, solution hundred patched up the diet of seed meal supplement within 20 days
With high-fat control diet) collect embodiment 1 the animal excrement.These excrement are dried and freeze.
9.1.2.RNA is extracted and is quantified
Freezing feces sample is added to 10 times of volumes- ICE (Applied Biosystems,
Foster City, CA, USA) in up at least for 24 hours.Total serum IgE uses excrement total serum IgE purification kit (Stool Total RNA
Purification Kit) (Norgen Biotek Corp., Canada) prepared according to manufacturers protocol.
The quantity and purity of the isolated RNA is verified by spectrophotometry (A260/A280 ratio).For
Every a sample uses 250ng total serum IgE and PrimeScriptTMRT kit (PrimeScriptTM RT reagent kit)
(Takara Bio Inc., Shiga, Japan) prepares cDNA according to manufacturers protocol.
Implemented using 7500 real-time PCR system of AB (Applied Biosystems, Foster City, CA, USA) real
When PCR enterobacteria 16S rRNA gene expression is quantified.Using SYBR Premix Ex Taq (Takara Bio Inc.,
Shiga, Japan) implement double amplification.Implemented using the amplification of primer shown in table 1 using following temperature curve: one is followed
Ring carries out 30 seconds at 95 DEG C, and carry out 40 circulations below: denaturation carries out 5~10s at 95 DEG C, anneals under optimum temperature
(annealating) 5~15s and extend 20s at 72 DEG C.
Table 1
9.2.As a result
Feeding patches up the quantitative real-time PCR knot of the fecal specimens of the hamster of the high fat diet of seed meal containing Chardonnay or solution hundred
Fruit shows that the enteric microorganism is adjusted by consuming the powder.It is surveyed in the fecal matter of the hamster of four kinds of diet of feeding
The total bacteria levels obtained are as shown in figure 20.The measurement level of bacterial subpopulations is as shown in figures 21-26.
Feeding supplements the hamster fecal specimens of the high fat diet of Chardonnay seed meal compared to high-fat control described in feeding
The hamster fecal specimens of diet show Bifidobacterium, and Lactobacillus and the horizontal of Enterobacter significantly reduce, and intestines ball
The level that Pseudomonas, fusobacterium IV groups (cluster) bacteriums and bacteroides fragilis belong to dramatically increases.
Feeding supplement solution hundred patches up the hamster fecal specimens of the high fat diet of seed meal compared to high-fat control described in feeding
The hamster fecal specimens of diet show the significant decrease of enterobacteria level, and enterococcus spp and bacteroides fragilis group's level significantly increase
Add.
10.Specific embodiment and document introduce
All publications quoted in the application, patent, patent application and other documents are all complete with it for all purposes
Text is incorporated herein by reference, and degree is each referred to such as each single publication, patent, patent application and other documents
It is incorporated herein by reference for all purposes out.
Although various specific embodiments have had been illustrated and described, it is understood that, various change can
It enough makes without departing from the spirit and scope of the present invention.
Claims (1)
1. a kind of method for improving lipid-metabolism in mammal, including given to the mammal and effectively improve lipid-metabolism
Amount Chardonnay seed products.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261640622P | 2012-04-30 | 2012-04-30 | |
US61/640,622 | 2012-04-30 | ||
US201261691515P | 2012-08-21 | 2012-08-21 | |
US61/691,515 | 2012-08-21 | ||
US201361798992P | 2013-03-15 | 2013-03-15 | |
US61/798,992 | 2013-03-15 | ||
CN201380026061.9A CN104519895B (en) | 2012-04-30 | 2013-04-29 | The therapeutical uses of Chardonnay seed products |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380026061.9A Division CN104519895B (en) | 2012-04-30 | 2013-04-29 | The therapeutical uses of Chardonnay seed products |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110433230A true CN110433230A (en) | 2019-11-12 |
Family
ID=48430944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910426268.4A Pending CN110433230A (en) | 2012-04-30 | 2013-04-29 | The therapeutical uses of Chardonnay seed products |
CN201380026061.9A Active CN104519895B (en) | 2012-04-30 | 2013-04-29 | The therapeutical uses of Chardonnay seed products |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380026061.9A Active CN104519895B (en) | 2012-04-30 | 2013-04-29 | The therapeutical uses of Chardonnay seed products |
Country Status (13)
Country | Link |
---|---|
US (4) | US10105409B2 (en) |
EP (1) | EP2844266A2 (en) |
JP (1) | JP6562837B2 (en) |
KR (1) | KR102149348B1 (en) |
CN (2) | CN110433230A (en) |
AU (1) | AU2013256577B2 (en) |
BR (1) | BR112014026926B1 (en) |
CA (1) | CA2871265C (en) |
EA (1) | EA201491817A1 (en) |
IL (1) | IL235349B (en) |
IN (1) | IN2014DN09085A (en) |
NZ (1) | NZ701607A (en) |
WO (1) | WO2013165921A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110433230A (en) | 2012-04-30 | 2019-11-12 | 索那麦提科有限责任公司 | The therapeutical uses of Chardonnay seed products |
WO2015164341A1 (en) * | 2014-04-21 | 2015-10-29 | Sonomaceuticals, Llc | Therapeutic use of grape seed products |
MX2016013993A (en) * | 2014-05-30 | 2017-01-11 | Shaklee Corp | Chardonnay grape seed extract. |
US10709751B2 (en) | 2014-05-30 | 2020-07-14 | Shaklee Corporation | Chardonnay grape seed extract |
EP3233101A4 (en) | 2014-12-20 | 2018-08-01 | Sonomaceuticals, LLC | Grape products for nonalcoholic fatty liver disease and other uses |
IL283877B (en) | 2015-05-06 | 2022-07-01 | Snipr Tech Ltd | Altering microbial populations & modifying microbiota |
ITUB20154797A1 (en) * | 2015-10-20 | 2016-01-20 | Francesco Donati | Set of powders for the extraction of drinks, and method for the realization of such set |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
WO2018109665A1 (en) * | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate bacteria in a companion animal |
KR102037897B1 (en) * | 2017-12-26 | 2019-10-30 | 한양대학교 산학협력단 | Composition for Preventing or Treating Obesity Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour |
KR102037898B1 (en) * | 2017-12-26 | 2019-10-30 | 한양대학교 산학협력단 | Composition for Preventing or Treating Hepatic Steatosis Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
KR102217834B1 (en) * | 2018-11-13 | 2021-02-19 | 한양대학교 산학협력단 | Composition for Preventing or Treating Obesity Comprising Heat-killed Lactic Acid Bacteria from Kefir and Grape Seed Flour |
JP7279943B2 (en) * | 2020-07-03 | 2023-05-23 | 株式会社エーゼット | Menopause improving agent containing grape seed extract |
RU2747660C1 (en) * | 2020-07-06 | 2021-05-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный технологический университет" (ФГБОУ ВО "КубГТУ") | Method for personifying nutrition taking into account genetically determined factors |
CA3229785A1 (en) | 2020-10-16 | 2022-04-21 | Sonomaceuticals, Llc | Food compositions incorporating agricultural marc, and methods of producing thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005048719A1 (en) * | 2003-11-17 | 2005-06-02 | Wisconsin Alumni Research Foundation | Polyphenol-containing stem and vine extracts and methods of use |
CN1947570A (en) * | 2006-11-07 | 2007-04-18 | 西北农林科技大学 | Method for producing capsule contg. super-fine powder of grape seeds |
CN101277616A (en) * | 2005-09-28 | 2008-10-01 | 美露香株式会社 | Process for producing fruit with enhanced alpha-aminobutyric acid content |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1951200A (en) | 2000-02-28 | 2001-08-30 | Vo Hanh Nhu Thi | Seedless chardonnay |
US20020192314A1 (en) * | 2001-03-06 | 2002-12-19 | Cho Suk H. | Dietary supplement compositions |
KR100448447B1 (en) * | 2002-12-17 | 2004-09-13 | 주식회사 엔바이오테크놀러지 | Composition comprising the extract of grape seed having α-glucosidase inhibitory activity, the preparation method and the use thereof |
US20060172012A1 (en) | 2005-01-28 | 2006-08-03 | Finley John W | Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
US20090082738A1 (en) | 2007-09-24 | 2009-03-26 | Vad Vijay B | Natural Anti-Inflammatory Agents for Reducing Pain |
CN102612564B (en) | 2009-04-10 | 2015-08-26 | 齐海燕 | New anti-ageing reagent and discrimination method thereof |
US20110217417A1 (en) * | 2009-05-04 | 2011-09-08 | Daniel Perlman | Phenolic antioxidant-supplemented infusion beverage |
DE202009013228U1 (en) | 2009-09-30 | 2011-02-10 | Tavarlin Ag | Gluten-free foods |
CN110433230A (en) * | 2012-04-30 | 2019-11-12 | 索那麦提科有限责任公司 | The therapeutical uses of Chardonnay seed products |
WO2015164341A1 (en) | 2014-04-21 | 2015-10-29 | Sonomaceuticals, Llc | Therapeutic use of grape seed products |
-
2013
- 2013-04-29 CN CN201910426268.4A patent/CN110433230A/en active Pending
- 2013-04-29 JP JP2015510368A patent/JP6562837B2/en active Active
- 2013-04-29 BR BR112014026926-2A patent/BR112014026926B1/en active IP Right Grant
- 2013-04-29 CA CA2871265A patent/CA2871265C/en active Active
- 2013-04-29 EP EP13722639.5A patent/EP2844266A2/en active Pending
- 2013-04-29 IN IN9085DEN2014 patent/IN2014DN09085A/en unknown
- 2013-04-29 WO PCT/US2013/038696 patent/WO2013165921A2/en active Application Filing
- 2013-04-29 KR KR1020147031337A patent/KR102149348B1/en active IP Right Grant
- 2013-04-29 AU AU2013256577A patent/AU2013256577B2/en active Active
- 2013-04-29 CN CN201380026061.9A patent/CN104519895B/en active Active
- 2013-04-29 EA EA201491817A patent/EA201491817A1/en unknown
- 2013-04-29 NZ NZ701607A patent/NZ701607A/en unknown
- 2013-04-29 US US14/398,093 patent/US10105409B2/en active Active
-
2014
- 2014-10-27 IL IL235349A patent/IL235349B/en active IP Right Grant
-
2018
- 2018-09-28 US US16/145,595 patent/US10772924B2/en active Active
-
2020
- 2020-09-14 US US17/020,533 patent/US11723943B2/en active Active
-
2023
- 2023-06-22 US US18/339,310 patent/US20240024404A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005048719A1 (en) * | 2003-11-17 | 2005-06-02 | Wisconsin Alumni Research Foundation | Polyphenol-containing stem and vine extracts and methods of use |
CN101277616A (en) * | 2005-09-28 | 2008-10-01 | 美露香株式会社 | Process for producing fruit with enhanced alpha-aminobutyric acid content |
CN1947570A (en) * | 2006-11-07 | 2007-04-18 | 西北农林科技大学 | Method for producing capsule contg. super-fine powder of grape seeds |
Non-Patent Citations (12)
Also Published As
Publication number | Publication date |
---|---|
CN104519895B (en) | 2019-06-11 |
US20190269748A1 (en) | 2019-09-05 |
US20240024404A1 (en) | 2024-01-25 |
EA201491817A1 (en) | 2015-04-30 |
US11723943B2 (en) | 2023-08-15 |
US20150132419A1 (en) | 2015-05-14 |
EP2844266A2 (en) | 2015-03-11 |
US10772924B2 (en) | 2020-09-15 |
KR20150018784A (en) | 2015-02-24 |
KR102149348B1 (en) | 2020-08-31 |
CA2871265A1 (en) | 2013-11-07 |
JP2015523321A (en) | 2015-08-13 |
WO2013165921A3 (en) | 2014-01-03 |
BR112014026926A2 (en) | 2017-06-27 |
BR112014026926B1 (en) | 2021-03-09 |
IN2014DN09085A (en) | 2015-05-22 |
AU2013256577B2 (en) | 2018-03-01 |
US10105409B2 (en) | 2018-10-23 |
JP6562837B2 (en) | 2019-08-21 |
US20210236579A1 (en) | 2021-08-05 |
NZ701607A (en) | 2017-04-28 |
AU2013256577A1 (en) | 2014-11-20 |
WO2013165921A2 (en) | 2013-11-07 |
IL235349A0 (en) | 2014-12-31 |
IL235349B (en) | 2020-11-30 |
CN104519895A (en) | 2015-04-15 |
CA2871265C (en) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104519895B (en) | The therapeutical uses of Chardonnay seed products | |
Rolim | Development of prebiotic food products and health benefits | |
JP2021052756A (en) | Low bitter chicory products | |
KR20100076943A (en) | Dietary fiber composition comprising glucomannan, xanthan gum, alginate and lipid | |
CN1980682A (en) | Flaxseeds for body weight management | |
CN103653170A (en) | Stachyose probiotics solid beverage | |
JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
CN111011862A (en) | Edible composition, low glycemic index nutrition powder and preparation method thereof | |
CN105028642B (en) | A kind of jujube diet fiber health-care Yoghourt and preparation method thereof | |
Arslaner et al. | Functional ice cream technology | |
CN112136894A (en) | Nutritional dietary supplement food beneficial to cardiovascular health and preparation method and application thereof | |
JP2010053120A (en) | Skin improvement agent for oral, food containing the same, and method for improving skin | |
KR20160026595A (en) | Composition for preventing or improving obesity and obesity-related disease comprising mixture of Coix lacryma-jobi L. var., Lentinus edodes, Poncirus trifoliata Rafin and Corn silk | |
CN112626001B (en) | Probiotic composition for promoting growth of butyric acid bacteria and application thereof | |
Adelerin et al. | Pumpkin-based cookies formulated from optimized pumpkin flour blends: Nutritional and antidiabetic potentials | |
RU2289951C1 (en) | Method for sambook production | |
JP2020127392A (en) | Intestinal function-controlling medicine containing inulin | |
JP6173850B2 (en) | Muscle bulking agent, muscle bulking agent when used together with exercise, and food and drink for muscle weight gain | |
JP2011246414A (en) | Lipid metabolism promoter in muscular tissue | |
JP6206983B2 (en) | Lipid metabolism promoter in muscle tissue | |
Skiba | Determinants of the Quality of Food Preparations | |
SUBHASHREE et al. | Chia Seed (Salvia hispanica L.) a Novel Food | |
JP2022130294A (en) | Intestinal environment improver and composition | |
JP2020129986A (en) | Oral composition | |
CN110063477A (en) | It is a kind of with drop body fat, Weight-reducing jelly of blood lipid and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |